CORRECTION



Correction to: Gilteritinib monotherapy for relapsed/refractory *FLT3* mutated acute myeloid leukemia: a real-world, multi-center, matched analysis

Shai Shimony 1,2,3 · Jonathan Canaani 4 · Eitan Kugler 1,2 · Boaz Nachmias 5 · Ron Ram 2,6 · Israel Henig 7 · Avraham Frisch 7 · Chezi Ganzel 8 · Vladimir Vainstein 5 · Yakir Moshe 2,6 · Shlomzion Aumann 5 · Moshe Yeshurun 1,2 · Yishai Ofran 8 · Pia Raanani 1,2 · Ofir wolach 1,2

Published online: 23 July 2022

© Springer-Verlag GmbH Germany, part of Springer Nature 2022

Correction to: Annals of Hematology

https://doi.org/10.1007/s00277-022-04895-8

In the published paper, the author Israel Henig who also contributed to the manuscript was accidentally dropped from the co-author list.

The original article has been corrected.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1007/s00277-022-04895-8.

- Shai Shimony shaishimony@gmail.com
- ¹ Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- ⁴ Hematology Division, Faculty of Medicine, Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
- Department of Hematology, Hadassah Medical Center, Hebrew University Faculty, Jerusalem, Israel
- 6 BMT Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Department of Hematology and Bone Marrow Transplantation, Rappaport Faculty of Medicine - Technion, Rambam Health Care Campus, Haifa, Israel
- Department of Hematology, Shaare Zedek Medical Center, Hebrew University Faculty, Jerusalem, Israel

